Navigation Links
President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
Date:5/9/2008

biology and master's and doctoral degrees in human physiology from Wayne State University's School of Medicine. He completed a post-doctoral fellowship at the Sloan Kettering Memorial Cancer Center and sabbatical training at one of the Howard Hughes Medical Institute laboratories. A professor in the Department of Pediatrics at the University of Michigan until 2003, Dr. Long left the university to lead his biotechnology firm dedicated to fighting bone disease. He led the development of 15 patents at U-M, as well as three recent patents at Velcura. Dr. Long has served on multiple national grant review committees at the National Institutes of Health and other national organizations. He speaks at many scientific conferences, has been a reviewer for numerous scientific publications and authored more than 70 articles.

"Life sciences and biotechnology are strongly growing fields in Michigan and will provide novel therapies and medical devices to cure diseases," Dr. Long said. "It's a very exciting time to be in the field." More than 250 million people in the world suffer from bone diseases and Velcura Therapeutics is developing highly differentiated therapies such as VEL-0230, which just ended a successful Phase I clinical trial. These diseases have an overall 18.5 percent growth rate and the market for their treatment is expected to reach $65 billion by 2030.

Additional information about Leader & Innovator award is posted at http://www.ltu.edu/leaders and each spring a Grant Thornton Leader & Innovator of the Year is selected from among weekly honorees profiled in co-sponsor WWJ News Radio 950's Great Lakes IT Report.

About Velcura Therapeutics, Inc.

Velcura Therapeutics Inc. is an early stage biotechnology company headquartered in Ann Arbor, Michigan. Velcura's research focus is to understand human bone disease and to discover novel therapeutics that restore bone health. Velcura develops
'/>"/>

SOURCE Velcura Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Entrust Chairman, President and CEO Bill Conner to Present at 8th Annual State of Technology Luncheon
2. Basil Zimmo Joins Finesse Solutions as Vice-President of Software
3. Kendle Appoints Patricia Williams Vice President, Commercial Operations
4. Trisha Dowling Joins Biomatrica as Vice President, Sales and Marketing
5. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
6. Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc.
7. Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
8. Former GE, Kodak and SGS Executive Dan Kerpelman to Join Bio-Optronics as President and CEO
9. PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services
10. Robert W. Lee, Ph.D. Joins Particle Sciences as Vice President of Pharmaceutical Development
11. Veteran Drug Industry Executive to Become President of CTI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Pa. , May 23, 2013 ... research and advisory firms for specialized biopharmaceutical issues, ... hepatologists, and infectious disease specialists reported that in ... patients (e.g., intentionally delaying treatment) in anticipation of ... than six months ago, when only 6 percent ...
(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...
(Date:5/23/2013)... DIEGO , May 23, 2013  Verenium Corporation ... company focused on the development and commercialization of high-performance ... , Chief Financial Officer, will present at two upcoming ... Mr. Black will present at the Second Annual Marcum ... the Grand Hyatt Hotel in New York City.  The ...
(Date:5/23/2013)... 2013 SynCardia Systems, Inc. ( http://www.syncardia.com ... Health Canada and CE (Europe) approved Total Artificial Heart, ... which boasts more than 380,000 visitors annually, is featuring ... by the Freedom® portable driver as part of its ... exhibitions of its kind. , “BodyWorks combines the ...
Breaking Biology Technology:The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3
... (OTCQB: ILIU) today issued financial and operational results for ... December 31, 2010. "We made good ... with Stanford University, data from a clinical study was ... genetics has in improving weight loss.  Our Inherent Health ...
... FRANCISCO, March 21, 2011 VentiRx Pharmaceuticals, Inc., ... novel Toll-Like Receptor 8 (TLR8) agonists and antagonists ... diseases, announced today the presentation of positive clinical ... VTX-1463 for the treatment of allergic rhinitis. The ...
... SAN CARLOS, Calif., March 21, 2011 WaferGen ... ), a leading developer of state-of-the-art genomic analysis ... innovative genomic samples preparation, today announced they will ... gene expression profiling and target enrichment to enable ...
Cached Biology Technology:Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 2Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 3Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 4Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 5Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 6Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 7VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting 2WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 2WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 3WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 4
(Date:5/22/2013)... 2013 U.S. Forest Service scientists are part of ... from the TKF Foundation, will examine how collaborative planning ... recover from tragedy. , The TKF Foundation announced today ... selected for grant funding. In addition to research on ... recovery and resiliency, the 3-year, $585,000 grant will contribute ...
(Date:5/22/2013)... technique that can detect molecular variants in chemical mixtures ... the most important, though time-consuming, processes in analytical chemistry. ... Nature , post-doctoral researcher David Patterson, Professor of Physics ... for Free-Electron Laser Science (CFEL) in Hamburg, Germany developed ... identify molecular variants apart, and to determine how much ...
(Date:5/22/2013)... genetic engineering drastically reduces the time and effort ... workhorses of biotechnology, scientists are reporting. Published in ... method paves the way for more rapid development ... and other activities. , Keith Shearwin and colleagues ... the genetic material DNA into a bacterium,s genome ...
Breaking Biology News(10 mins):'Landscapes of Resilience' to study how people use nature as a source of recovery 2Detecting mirror molecules 2Detecting mirror molecules 3
... Biochemist Glenn King is searching for an alternative to ... one the world's most efficient insect predators -- spiders. ... large Australian spider with a bite that is deadly ... of venom for King's research. The spider "cooperates" by ...
... B cell chronic lymphocytic leukemia (B-CLL),is the most ... the,progressive accumulation of mature B lymphocytes in the ... that in the early stages,of disease, B-CLL is ... signals that trigger normal B cell death (apoptosis). ...
... rapid advancement of biomedical science and the development ... types of information from biomedical text has become ... quite useful for interpreting large amounts of high-throughput ... information related to gene functions from text has ...
Cached Biology News:Spider Venom Could Yield Eco-Friendly Insecticides 2Spider Venom Could Yield Eco-Friendly Insecticides 3
Peptide-affinity Purified Polyclonal Antibody to Purinergic Receptor P2Y12...
Purified anti-PXR...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
Purified anti-DNA-PKcs Phosphorylated (Thr2609)...
Biology Products: